Please login to the form below

Not currently logged in
Email:
Password:

Genmab appoints Tahamtan Ahmadi as chief medical officer, head of experimental medicines

Ahmadi joined Genmab in 2017, previously serving as senior vice president, head of oncology

Genmab has appointed Tahamtan Ahmadi to the newly created position of executive vice president and chief medical officer, head of experimental medicines.

Ahmadi joined Genmab in 2017, previously serving as senior vice president, head of oncology at the company.

Prior to Genmab, Ahmadi worked as head of experimental medicine and early development oncology at Janssen.

He is also a haematologist and oncology by training, with a MD from the University of Cologne as well as a PhD in immunology from the University of Freiburg.

In his new role at Genmab, Ahmadi he will lead research, discovery, regulatory and medical activities.

“As we continue to evolve and grow our organisation, I am delighted that Tahi [Ahmadi] will take on this exciting new role and further strengthen Genmab’s very strong executive management team,” said Jan van de Winkel, chief executive officer of Genmab.

“Given his proven track record of drug development leadership and innovative thinking, I am confident that Tahi [Ahmadi] will effectively drive our R&D teams alongside Judith to deliver on our promise to create, develop and bring truly differentiated next-generation antibody medicines to cancer patients,” he added.

23rd February 2021

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dovetail

We’re a specialist health consultancy that supports companies, healthcare professionals and patients to work hand in hand with a common...

Latest intelligence

Personalised medicine: driving a need for greater diversity in clinical trials
Kate Shaw, Innovative Trials' Founder & CEO, investigates one of the biggest challenges facing clinical research today....
Congresses and conferences
Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay...
Cervical Cancer Prevention Month
In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...